PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway/ferroptosis

• Published in: Biomedicine & pharmacotherapy Vol. 168; p. 115711
• Main Authors: Zhao, Mengnan, Lu, Tao, Bi, Guoshu, Hu, Zhengyang, Liang, Jiaqi, Bian, Yunyi, Feng, Mingxiang, Zhan, Cheng
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.12.2023; Elsevier
• Subjects: Animals; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Cisplatin - pharmacology; Cisplatin - therapeutic use; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - genetics; Esophageal squamous cell carcinoma; Esophageal Squamous Cell Carcinoma - pathology; Ferroptosis; Humans; Mice; NADP - metabolism; Paclitaxel - pharmacology; Paclitaxel - therapeutic use; Pentose Phosphate Pathway; PLK1; Polo-Like Kinase 1; Single-cell transcriptome sequencing; YY1 Transcription Factor - metabolism; PBS; HEK293T; Single-cell transcriptome sequencing; TSA; PLK1; HRP; Ferroptosis; PVDF; Chemoradiotherapy; ESCC; PPP; SDS-PAGE; scRNA-seq; FFPE; CNVs; CCK-8; Esophageal squamous cell carcinoma; GSH
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115711

Esophageal squamous cell carcinoma (ESCC) is the most common pathological type of esophageal cancer in China, accounting for more than 90 %. Most patients were diagnosed with advanced-stage ESCC, for whom new adjuvant therapy is recommended. Therefore, it is urgent to explore new therapeutic targets for ESCC. Ferroptosis, a newly discovered iron-dependent programmed cell death, has been shown to play an important role in carcinogenesis by many studies. This study explored the effect of Polo like kinase 1 (PLK1) on chemoradiotherapy sensitivity of ESCC through ferroptosis In this study, we knocked out the expression of PLK1 (PLK1-KO) in ESCC cell lines (KYSE150 and ECA109) with CRISPR/CAS9. The effects of PLK1-knock out on G6PD, the rate-limiting enzyme of pentose phosphate pathway (PPP), and downstream NADPH and GSH were explored. The lipid peroxidation was observed by flow cytometry, and the changes in mitochondria were observed by transmission electron microscopy. Next, through the CCK-8 assay and clone formation assay, the sensitivity to cobalt 60 rays, paclitaxel, and cisplatin were assessed after PLK1-knock out, and the nude mouse tumorigenesis experiment further verified it. The regulation of transcription factor YY1 on PLK1 was evaluated by dual luciferase reporter assay. The expression and correlation of PLK1 and YY1, and their impact on prognosis were analyzed in more than 300 ESCC cases from the GEO database and our center. Finally, the above results were further proved by single-cell sequencing. After PLK1 knockout, the expression of G6PD dimer and the level of NADPH and GSH in KYSE150 and ECA109 cells significantly decreased. Accordingly, lipid peroxidation increased, mitochondria became smaller, membrane density increased, and ferroptosis was more likely to occur. However, with the stimulation of exogenous GSH (10 mM), there was no significant difference in lipid peroxidation and ferroptosis between the PLK1-KO group and the control group. After ionizing radiation, the PLK1-KO group had higher lipid peroxidation ratio, more cell death, and was more sensitive to radiation, while exogenous GSH (10 mM) could eliminate this difference. Similar results could also be observed when receiving paclitaxel combined with cisplatin and chemoradiotherapy. The expression of PLK1, G6PD dimer, and the level of NADPH and GSH in KYSE150, ECA109, and 293 T cells stably transfected with YY1-shRNAs significantly decreased, and the cells were more sensitive to radiotherapy and chemotherapy. ESCC patients from the GEO database and our center, YY1 and PLK1 expression were significantly positively-correlated, and the survival of patients with high expression of PLK1 was significantly shorter. Further analysis of single-cell sequencing specimens of ESCC in our center confirmed the above results. In ESCC, down-regulation of PLK1 can inhibit PPP, and reduce the level of NADPH and GSH, thereby promoting ferroptosis and improving their sensitivity to radiotherapy and chemotherapy. Transcription factor YY1 has a positive regulatory effect on PLK1, and their expressions were positively correlated. PLK1 may be a target for predicting and enhancing the chemoradiotherapy sensitivity of ESCC. [Display omitted] •PLK1 inhibits ferroptosis of ESCC by promoting the pentose phosphate pathway.•Down-regulation of PLK1 improves the sensitivity of ESCC to chemoradiotherapy.•YY1 positively regulates the expression of PLK1.•YY1 and PLK1 are overexpressed in cancer cells of ESCC.